Shares of AdaptHealth(NASDAQ: AHCO) were skyrocketing Tuesday morning, up 29.7% as of 10:56 a.m. ET. That huge gain came after the home medical equipment and supplies provider announced its 2023 fourth-quarter and full-year results before the opening bell.
AdaptHealth reported net revenue in the fourth quarter of $858.2 million, up 10% year over year. The average analysts' estimate was for revenue of $825.4 million. The company posted a net loss in Q4 of $254.5 million, or $1.91 per share. This result was well below the consensus earnings estimate of $0.18 per share.
Why did AdaptHealth stock jump after missing Q4 earnings estimates?
When companies miss analysts' earnings estimates, their stocks typically don't soar -- they fall. Why did investors react so positively to AdaptHealth's Q4 update? As you might expect, there was more to the story.
AdaptHealth wrote down $318.9 million of goodwill in the fourth quarter. Without this accounting move, the company would have posted a solid profit.
Investors also cheered AdaptHealth's 2024 guidance. The company expects to generate net revenue of between $3.25 billion and $3.35 billion this year. Although the midpoint of this range equates to growth of only 3%, it doesn't include the impact of acquisitions that haven't closed yet. AdaptHealth also projected free cash flow (FCF) of between $150 million and $180 million, up nicely from the $143.2 million in FCF generated in 2023.
Is AdaptHealth stock a buy?
AdaptHealth won't be appealing to income investors, since the company doesn't pay a dividend. Growth investors probably won't find the stock all that attractive either.
However, I think that value investors might want to take a hard look at AdaptHealth. Its shares currently trade at only 11 times forward earnings, and its forward price-to-FCF ratio is a low 8.2 based on the midpoint of the company's FCF guidance range.
Should you invest $1,000 in AdaptHealth right now?
Before you buy stock in AdaptHealth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AdaptHealth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than tripled the return of S&P 500 since 2002*.
*Stock Advisor returns as of February 26, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
